Chester County News and Community Website
BERWYN, PA — In a move to promote diversity in clinical trials, Chester County-based Mural Health has announced the “Harley Jacobsen Clinical Trial Participation Income Exemption Act,” a landmark legislation …
Mural Health Champions Revolutionary Bill for Enhanced Diversity in Clinical Trials Read More
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced initial positive results from a pilot study of its pain management drug candidate, Probudur™. The study was conducted under an …
Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study Read More
SPRING HOUSE, PA — Johnson & Johnson recently announced that its investigational drug, nipocalimab, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). The designation …
FDA Grants Breakthrough Therapy Status to Johnson & Johnson’s Nipocalimab for HDFN Treatment Read More SPRING HOUSE, PA — In a remarkable breakthrough for the healthcare industry, Johnson & Johnson’s investigational targeted oral peptide, JNJ-2113, has displayed positive results in a Phase 2b study for …
Promising Breakthrough in Psoriasis Treatment: Johnson & Johnson’s JNJ-2113 Achieves Stellar Results Read More
WILMINGTON, DE — In an informing breakthrough, scientists at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have discovered a critical link between two chief cellular pathways implicated in …
Ground Breaking Research Sheds Light on New Potential Treatment Target for Colorectal Cancer Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS this week announced a delay in the release of Phase III study data for its promising Parkinson’s Disease drug, buntanetap. The postponement …
Annovis Bio Postpones Release of Phase III Data for Parkinson’s Disease Drug, Buntanetap Read More
WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …
Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …
Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …
Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More